<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110720</url>
  </required_header>
  <id_info>
    <org_study_id>AL-108-231</org_study_id>
    <nct_id>NCT01110720</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy</brief_title>
  <official_title>A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allon Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of davunetide for the&#xD;
      treatment of Progressive Supranuclear Palsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2/3,Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and&#xD;
      Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy, as measured by change from baseline scores of the Progressive Supranuclear Palsy Rating Scale (PSPRS) at 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy, as measured by the change from baseline of the Schwab and England Activities of Daily Living Scale (SEADL) at 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by reported AEs, electrocardiograms (ECG), nasal examinations and clinical laboratory measures</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy, as measured by the Clinical Global Impression of Change (CGI-C) at 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy, as measured by change from baseline of ventricular volumes measured by volumetric brain MRI at 52 weeks.</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">313</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Davunetide 30 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Davunetide</intervention_name>
    <description>Davunetide Nasal Spray 30 mg BID IN 52 weeks</description>
    <arm_group_label>Davunetide 30 mg BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Nasal Spray BID IN 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Probable or possible PSP defined as:&#xD;
&#xD;
               -  at least a 12-month history of postural instability or falls during the first 3&#xD;
                  years that symptoms are present; and&#xD;
&#xD;
               -  at screening, a decreased downward saccade velocity defined as observable eye&#xD;
                  movement (deviation from the &quot;main sequence&quot; linear relationship between saccade&#xD;
                  amplitude and saccade velocity) or, supranuclear ophthalmoplegia defined as 50%&#xD;
                  reduction in upward gaze or 30% reduction in downward gaze; and&#xD;
&#xD;
               -  age at symptom onset of 40 to 85 years by history; and&#xD;
&#xD;
               -  an akinetic-rigid syndrome with prominent axial rigidity.&#xD;
&#xD;
          -  Aged 41 to 85 years at the time of screening.&#xD;
&#xD;
          -  Judged by investigator to be able to comply with neuropsychological evaluation at&#xD;
             baseline and throughout the study.&#xD;
&#xD;
          -  Must have reliable caregiver accompany subject to all study visits. Caregiver must&#xD;
             read, understand, and speak local language fluently to ensure comprehension of&#xD;
             informed consent form and informant-based assessments of subject. Caregiver must also&#xD;
             have frequent contact with subject (at least 3 hours per week at one time or at&#xD;
             different times) and be willing to monitor study medication compliance and the&#xD;
             subject's health and concomitant medications throughout the study.&#xD;
&#xD;
          -  Modified Hachinski score ≤ 3 (Appendix 7). This modified Hachinski will not include&#xD;
             the focal neurological signs, symptoms or pseudobulbar affect questions, given the&#xD;
             prominence of all 3 in PSP.&#xD;
&#xD;
          -  Score ≥ 15 on the mini-mental state examination (MMSE) at screening (Visit 1).&#xD;
&#xD;
          -  Written informed consent provided by subject (or legally-appointed representative, as&#xD;
             appropriate) and caregiver (if not the legally-appointed representative) who are both&#xD;
             fluent local language speakers.&#xD;
&#xD;
          -  Subject resides outside a skilled nursing facility or dementia care facility at the&#xD;
             time of screening, and admission to such a facility is not planned. Residence in an&#xD;
             assisted living facility is allowed.&#xD;
&#xD;
          -  If the subject is receiving levodopa/carbidopa, levodopa/benserazide, a dopamine&#xD;
             agonist, catechol-o-methyltransferase (COMT) inhibitor, or other Parkinson's&#xD;
             medication,with teh exception of Azilect(rasagiline), the dose must have been stable&#xD;
             for at least 60 days prior to the screening visit (Visit 1) and must remain stable for&#xD;
             the duration of the study. No such medication can be initiated during the study.&#xD;
             Subjects receiving rasagiline or CoQ10 must be on a stable dose for at least 90 days&#xD;
             prior to the screening visit.&#xD;
&#xD;
          -  Able to tolerate the MRI scan during screening with either no sedation or low dose&#xD;
             lorazepam.&#xD;
&#xD;
          -  Able to ambulate independently or with assistance defined as the ability to take at&#xD;
             least 5 steps with a walker (guarding is allowed provided there is no contact) or the&#xD;
             ability to take at least 5 steps with the assistance of another person who can only&#xD;
             have contact with one upper extremity.&#xD;
&#xD;
          -  Presence of symptoms for less than 5 years or the presence of symptoms for more than 5&#xD;
             years with a PSPRS baseline score ≥ 40.&#xD;
&#xD;
          -  Stable on all other chronic medications for at least 30 days prior to the screening&#xD;
             visit (Visit 1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insufficient fluency in local language to complete neuropsychological and functional&#xD;
             assessments.&#xD;
&#xD;
          -  A diagnosis of Amyotrophic Lateral Sclerosis or other motor neuron disease.&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Abrupt onset of symptoms defined in inclusion criteria 1 associated with ictal&#xD;
                  events,&#xD;
&#xD;
               -  Head trauma related to onset of symptoms defined in inclusion criteria 1,&#xD;
&#xD;
               -  Severe amnesia within 6 months of the symptoms defined in inclusion criteria 1,&#xD;
&#xD;
               -  Cerebellar ataxia,&#xD;
&#xD;
               -  Choreoathetosis,&#xD;
&#xD;
               -  Early, symptomatic autonomic dysfunction; or&#xD;
&#xD;
               -  Tremor while at rest.&#xD;
&#xD;
          -  Presence of other significant neurological or psychiatric disorders including (but not&#xD;
             limited to) Alzheimer's disease; dementia with Lewy bodies; prion disease; Parkinson's&#xD;
             disease (which has not subsequently been revised to PSP); any psychotic disorder;&#xD;
             severe bipolar or unipolar depression; seizure disorder; tumor or other&#xD;
             space-occupying lesion; or history of stroke or head injury with loss of consciousness&#xD;
             for at least 15 minutes within the past 20 years.&#xD;
&#xD;
          -  Within 4 weeks of screening or during the course of the study, concurrent treatment&#xD;
             with memantine; acetylcholinesterase inhibitors; antipsychotic agents (other than&#xD;
             quetiapine) or mood stabilizers (e.g., valproate, lithium); or benzodiazepines (except&#xD;
             as below).&#xD;
&#xD;
               -  Low dose lorazepam (not more than 2 mg) may be used for sedation prior to MRI&#xD;
                  scans for those subjects requiring sedation. Neuropsychological testing may not&#xD;
                  be performed after lorazepam administration.&#xD;
&#xD;
               -  Subjects who take short acting benzodiazepines (only temazepam or zolpidem are&#xD;
                  allowed) for sleep may continue to do so if they have been on a stable dose for&#xD;
                  30 days prior to screening.&#xD;
&#xD;
               -  Clonazepam may be used for treatment of dystonia or painful rigidity associated&#xD;
                  with PSP if the dose has been stable for 90 days prior to screening and is not&#xD;
                  expected to change during the course of the study.&#xD;
&#xD;
          -  Treatment with lithium, methylene blue, tramiprosate, ketone bodies, latrepirdine, or&#xD;
             any putative disease-modifying agent directed at tau within 90 days of screening.&#xD;
&#xD;
          -  A history of alcohol or substance abuse within 1 year prior to screening and deemed to&#xD;
             be clinically significant by the site investigator.&#xD;
&#xD;
          -  Any malignancy (other than non-metastatic dermatological conditions) within 5 years of&#xD;
             the screening visit (Visit 1) or current clinically significant hematological,&#xD;
             endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disease.&#xD;
             For the non-cancer conditions, if the condition has been stable for at least one year&#xD;
             before the screening visit and is judged by the site investigator not to interfere&#xD;
             with the subject's participation in the study, the subject may be included.&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities at screening, including creatinine ≥&#xD;
             2.5 mg/dL, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3&#xD;
             times the upper limit of the normal reference range, vitamin B12 below the laboratory&#xD;
             normal reference range, or thyroid stimulating hormone TSH above laboratory normal&#xD;
             reference range.&#xD;
&#xD;
          -  The systolic blood pressure measurement is &gt; 190 or &lt; 85 mm Hg. The diastolic blood&#xD;
             pressure measurement is &gt; 105 or &lt; 50 mm Hg at screening.&#xD;
&#xD;
          -  Abnormal ECG tracing at screening and judged to be clinically significant by the site&#xD;
             investigator.&#xD;
&#xD;
          -  Treatment with any investigational drugs or device within 90 days of screening.&#xD;
&#xD;
          -  Known history of serum or plasma progranulin level less than one standard deviation&#xD;
             below the normal subject mean for the laboratory performing the assay.&#xD;
&#xD;
          -  Known presence of known disease-associated mutation in TDP-43, PGRN, CHMPB2, or VCP&#xD;
             genes or any other frontotemporal lobar degeneration (FTLD) causative genes not&#xD;
             associated with underlying tau pathology (e.g., Chromosome 9 associated FTD).&#xD;
&#xD;
          -  History of deep brain stimulator (DBS) surgery other than sham surgery for DBS&#xD;
             clinical trial.&#xD;
&#xD;
          -  History of early, prominent rapid eye movement (REM) sleep behavior disorder.&#xD;
&#xD;
          -  Women who are pregnant or lactating and women of childbearing potential who are not&#xD;
             using at least two different forms of medically recognized and highly effective&#xD;
             methods of birth control, resulting in a low failure rate when used consistently and&#xD;
             correctly such as implants, injectables, combined oral contraceptives, some IUDs,&#xD;
             sexual abstinence or vasectomised partner.&#xD;
&#xD;
          -  An employee or relative of an employee of the Sponsor, a clinical site, or Contract&#xD;
             Research Organization participating in the study.&#xD;
&#xD;
          -  Significant anatomical nasal abnormality (e.g., septal deviation obstructing airflow&#xD;
             to at least one nostril or septal perforation) or history of nasal turbinate surgery.&#xD;
&#xD;
          -  History of a clinically significant medical condition that would interfere with the&#xD;
             subject's ability to comply with study instructions, would place the subject at&#xD;
             increased risk, or might confound the interpretation of the study results.&#xD;
&#xD;
          -  Contraindication to MRI examination for any reason (e.g., severe claustrophobia,&#xD;
             ferromagnetic metal in body).&#xD;
&#xD;
          -  Structural abnormality on MRI that precludes diagnosis of PSP, such as cortical&#xD;
             infarct in brain region that might account for subject's symptoms.&#xD;
&#xD;
          -  In subjects receiving anti-Parkinson's Disease medication at the time of screening, in&#xD;
             the opinion of the investigator substantial worsening of motor signs or symptoms&#xD;
             compared with normal functioning following overnight withdrawal of the anti-Parkinson&#xD;
             medication.&#xD;
&#xD;
          -  Known hypersensitivity to davunetide or any ingredient of the formulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Boxer, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memory and Aging Center, University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muhammed Ali Parkinson Center and Movement Disorders Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, AZ</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine - UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD/VA Neurology Service</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Memory and Aging Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute - Rocky Mountain Movement Disorders Ctr, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Parkinson Disease &amp; Movement Disorders Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Division of Movement Disorders</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Department of Neuology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester, MN</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - Robert Wood Johnson Medical Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of North Carolina Department of Neurology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical CenterNI Movement Disorders Center</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Center for Alzheimer's Care, Imaging &amp;Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Sciences Health Center University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease &amp; Movement Disorders Clinic</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Notre Dame Hospital Unité de Troubles du Mouvement</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humboldt University Charité</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologisch Klinik der Ruhr-Universität im St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Carus an der Technischen Universität</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena Klinik</name>
      <address>
        <city>Kassel</city>
        <zip>34128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock Zentrum für Nervenheilkunde und Poliklinik</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts- und Rehabilitationskliniken Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital</name>
      <address>
        <city>Haywards Heath</city>
        <zip>RH16 4EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Ageing Research Unit (CARU) Newcastle University</name>
      <address>
        <city>Newcastle</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Manchester Neuroscience Centre</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

